Please login to the form below

Not currently logged in
Email:
Password:

Bentley wins US intranasal technology patent protection

Bentley Pharmaceuticals has revealed that the US Patent and Trademark Office issued it with patent protection on its intranasal technology

US-based specialty pharmaceutical company, Bentley Pharmaceuticals, has received US Patent and Trademark Office recognition through the award of patent number 7,244,703 entitled "Pharmaceutical Compositions and Methods for Peptide Treatment."

The patent extends coverage for Bentley's current intranasal drug delivery technology employing CPE-215 beyond insulin to include delivery of other therapeutically effective, pharmaceutically active peptides, peptidomimetics and proteins.

In September 2006, Bentley received a US patent covering its intranasal delivery spray for insulin.

The new patent, which was issued from an application filed back in 2004, provides proprietary protection to Bentley for 20 years from the date of filing.

23rd July 2007

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Hamell

Hamell is a full-service agency with a clear focus on delivering evidence-based, sustained behaviour change. So, whether you are looking...

Latest intelligence

The Patient Will See You Now – The Evolution of the Doctor-Patient Relationship
The doctor-patient relationship is an ever changing one that changes as society changes. Technology then helps to drive this change along with a wide number of other factors....
Mind the Gap – Challenging Immunisation Apathy and Misinformation
world, the biggest challenges remain apathy and misinformation. Since a measles vaccine was introduced in the UK in 1968, Public Health England estimates that 20 million measles cases and 4,500...
Towards Better HCP Engagement – An Email Masterclass
6% of HCPs prefer being contacted by email, compared to 17% who favour the second most popular option: direct interaction with reps....